Supernus Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

43.30$ -0.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement SUPN
Line item	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0.31	0.64	2.74	0.01	0.06	0.08	0.38	2.41	2.82	4.16	5.67	7.56	7.30	9.69	10.67	10.82	10.94	11.83	12.74
Cost of Revenue	–	0.00	-0.62	-0.97	2.72	2.45	0.03	0.11	0.16	0.23	0.29	0.28	0.31	0.98	1.38	1.41	1.51	1.39	1.32
Gross Profit	0.31	0.64	3.36	0.98	0.06	0.08	0.34	2.30	2.66	3.93	5.38	7.27	6.99	8.72	9.29	9.40	9.44	10.43	11.42
Research & Development	1.39	2.20	2.11	2.54	2.21	1.35	0.54	0.39	0.57	0.83	0.93	1.65	1.28	1.41	1.66	1.21	1.65	1.94	1.88
Selling, General & Administrative	–	0.31	0.34	0.37	–	0.82	1.29	1.14	1.37	1.63	1.95	2.16	2.19	1.23	1.93	1.77	4.26	4.42	3.49
Total Operating Expenses	1.68	2.51	2.45	2.90	2.78	2.50	2.29	1.82	2.31	2.88	3.52	4.60	4.23	5.48	7.70	8.66	9.53	8.98	12.07
Operating Income	-1.37	-1.87	0.29	-2.90	-2.72	-2.42	-1.94	0.48	0.35	1.05	1.87	2.67	2.76	3.24	1.58	0.75	-0.09	1.46	-0.65
Interest Expense	0.13	0.63	0.01	0.01	0.13	0.20	0.25	0.11	0.09	0.10	0.03	0.33	0.42	0.44	0.43	0.11	0.04	0.00	0.00
Pre-Tax Income	-1.25	-2.42	0.30	-2.85	-2.85	-2.65	-2.90	0.39	0.29	0.97	1.89	2.59	2.74	3.14	1.35	0.98	0.05	1.75	-0.87
Income Tax Expense	0.13	0.08	0.27	-0.03	-1.17	0.07	0.22	0.08	0.02	-0.79	0.81	0.54	0.64	0.78	0.36	0.00	0.03	0.43	-0.19
Net Income	-1.25	-2.42	0.03	-2.78	4.04	-2.65	-2.90	0.39	0.27	1.76	1.07	2.05	2.10	2.36	0.98	0.98	0.02	1.32	-0.68
EBITDA	-1.18	-1.71	0.38	-2.76	-2.65	-2.40	-2.63	-0.09	0.43	1.09	2.02	2.80	3.35	3.92	2.38	2.49	1.62	3.19	0.75

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?